Tratamiento de situaciones clínicas difíciles en pacientes que presentan artritis reumatoide con hepatitis

Farah, 2008, Granulomatous hepatitis associated with Etanercept therapy, J Rheumatol, 35, 349 Ozorio, 2007, Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis, Med J Aust, 187, 524, 10.5694/j.1326-5377.2007.tb01396.x Calabrese, 2004, Safety of anti-tumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection, Ann Rheum Dis, 63, ii18, 10.1136/ard.2004.028209 Yeo, 2000, Frecuency of hepatitis B reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors, J Med Virol, 62, 299, 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0 Hsieh, 2008, Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B cell lymphoma, J Clin Oncol, 26, 2584, 10.1200/JCO.2007.15.4807 Yeo, 2004, Lamivudine for prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy, J Clin Oncol, 5, 927, 10.1200/JCO.2004.05.161 Firpi, 2008, Management of viral hepatitis in hematologic malignancies, Blood Rev, 22, 117, 10.1016/j.blre.2008.02.001 He, 2008, The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab containing regimens for lymphoma, Ann Hematol, 87, 481, 10.1007/s00277-008-0454-3 Hui, 2005, Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy, Gut, 54, 1597, 10.1136/gut.2005.070763 Calabrese, 2006, Hepatitis B virus (HBV) reactivation with immunosupressive therapy in rheumatic diseases: Assessment and preventive strategies, Ann Rheum Dis, 65, 983, 10.1136/ard.2005.043257 Carroll, 2008, Use of tumor necrosis factor α inhibitors in patients with chronic hepatitis B infection, Semin Arthritis Rheum, 10.1016/j.semarthrit.2007.10.011 Narváez, 1998, Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy, J Rheumatol, 25, 2037 Flowers, 1990, Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low doses methotrexate therapy, Ann Intern Med, 112, 381, 10.7326/0003-4819-112-5-381 Gwak, 2007, Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate, Clin Exp Rheumatol, 25, 888 Bellisai, 2007, Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection, Clin Rheumat, 26, 1127, 10.1007/s10067-006-0412-1 Wendling, 2005, Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy, Ann Rheum Dis, 64, 788, 10.1136/ard.2004.031187 Ojiro, 2008, Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab, J Gastroenterol, 43, 397, 10.1007/s00535-008-2165-x Ito, 2001, Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low dose methotrexate therapy in a rheumatoid arthritis patient, Arthritis Rheum, 41, 339, 10.1002/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q Roux, 2006, Safety of anti-TNF-α therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis, Rheumatology, 45, 1294, 10.1093/rheumatology/kel123 Ostuni, 2003, Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid artritis treated with low infliximab dose methotrexate, Ann Rheum Dis, 65, 686, 10.1136/ard.62.7.686 Michel, 2003, Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still's disease, J Rheumatol, 30, 1624 Ferri, 2008, Safety of anti-tumor necrosis factor –α therapy in patients with rheumatoid arthritis and crhonic hepatitis B virus infection, J Rheumatol, 35, 10 Raftery, 2006, Chronic viral hepatitis and TNF-alpha blockade, Rheumatology, 45, 1294 Raftery, 2007, Chronic viral hepatitis and TNF-alpha blockade, Rheumatology, 46, 1382, 10.1093/rheumatology/kem082 Esteve, 2004, Chronic hepatitis B reactivation following infliximab therapy in Chron's disease patients: Needs for primary prophylaxis, Gut, 53, 1363, 10.1136/gut.2004.040675 Oniankitan, 2004, Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C, J Rheumatol, 31, 107 Benucci, 2008, Effect of etanercept pus lamivudine in a patients with rheumatoid arthritis and viral hepatitis B, J Clin Rheumatol, 14, 245, 10.1097/RHU.0b013e318181b89d Cansu, 2008, Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis, J Rheumatol, 35, 421 Madonia, 2007, Occult hepatitis B and infliximab-induced HBV reactivation, Inflamm Bowel Dis, 13, 508, 10.1002/ibd.20035 Millonig, 2006, Subfulminant hepatitis B after infliximab in Crohn's disease: Need for HBV- screening?, World J Gastroenterol, 12, 974, 10.3748/wjg.v12.i6.974 Parke, 2004, Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection, Arthritis Rheum, 51, 800, 10.1002/art.20702 De Simone, 2006, Etanercept therapy in two patients with psoriasis and concomitant hepatitis C, J Am Acad Dermatol, 54, 1102, 10.1016/j.jaad.2005.11.1035 Rokbsar, 2006, Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis and concomitant hepatitis C, J Am Acad Dermatol, 54, 361, 10.1016/j.jaad.2005.05.043 Linardaki, 2007, Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection, J Rheumatol, 3, 1353 Marotte, 2007, Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus, Rheumatology, 46, 97, 10.1093/rheumatology/kel191 Peterson, 2003, Effect of tumor necrosis factor α antagonist on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection, Ann Rheum Dis, 62, 1078, 10.1136/ard.62.11.1078 Vauloup, 2006, Effects of tumor necrosis factor antagonist on hepatitis C- related immunological abnormalities, Eur Cytokine Netw, 17, 290 Zein, 2005, Etanercept as an adjuvant to interferon and ribavarin in treatment-naive patients with crhonic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study, J Hepatol, 42, 315, 10.1016/j.jhep.2004.11.025 Han, 2006, Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B, Drugs, 66, 1831, 10.2165/00003495-200666140-00005 Antonelli, 2008, HCV infection: Pathogenesis, clinical manifestations and therapy, Clin Exp Rheum, 26, S39 Nathan, 2006, Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach, J Gastroenterol and Hepatol, 21, 1366, 10.1111/j.1440-1746.2006.04559.x Shibolet, 2002, Lamivudine therapy for prevention of immunosuppressive induced hepatitis B virus reactivation in hepatitis B surface antigens carriers, Blood, 100, 391, 10.1182/blood.V100.2.391